Antifungal Therapy for Oropharyngeal Candidiasis

Clinical Evaluation

Symptoms such as white patches on the mucous membranes, oral burning, weight loss, diarrhea, and weakness in a patient with HIV infection suggest oropharyngeal candidiasis with possible esophageal involvement 1, 2
Systemic symptoms like weight loss, diarrhea, and weakness may indicate esophageal candidiasis or disseminated infection 2, 4

The Infectious Diseases Society of America recommends fluconazole 200-400 mg (3-6 mg/kg) orally per day for 14-21 days as the first-line treatment for oropharyngeal candidiasis with possible esophageal involvement 1, 2, 5
For patients who cannot take oral medications, intravenous fluconazole 400 mg (6 mg/kg) per day is recommended 2
Alternative treatments include echinocandins (micafungin 150 mg/day, caspofungin 70 mg loading dose, then 50 mg/day, or anidulafungin 200 mg/day) 2, 4

Continuing antiretroviral therapy is crucial to reduce the frequency of candidiasis recurrences 2, 6, 4
For frequent recurrences, maintenance therapy with fluconazole 100-200 mg three times a week may be considered 2, 4

Local antiseptic therapy (mouthwashes) is not effective for systemic candidiasis and should only be used as an adjunct to systemic therapy 3
Immunomodulatory therapy is not recommended as a primary treatment for candidiasis in HIV-infected patients and may be considered only as adjunctive therapy in refractory cases 2
Potential drug interactions between antifungal medications and antiretroviral therapy should be evaluated 2
If standard therapy is ineffective, resistance to azoles should be excluded, and alternative treatment regimens should be considered 2, 3

Clinical improvement should occur within 48-72 hours of starting therapy 3
Treatment should be continued for at least 14 days and for at least 7 days after all symptoms have resolved 1, 2
If there is no improvement within 1 week, resistance should be considered, and the antifungal medication should be changed 2, 3